Nico Gagelmann, Danai Dima, Maximilian Merz, Hamza Hashmi, Nausheen Ahmed, Natalia Tovar, Aina Oliver-Caldés, Friedrich Stölzel, Kristin Rathje, Luise Fischer, Patrick Born, Lisa Schäfer, Anca-Maria Albici, Natalie Schub, Shlomit Kfir-Erenfeld, Miri Assayag, Nathalie Asherie, Gerald Georg Wulf, Soraya Kharboutli, Fabian Müller, Leyla Shune, James A Davis, Faiz Anwer, Vladan Vucinic, Uwe Platzbecker, Francis Ayuk, Nicolaus Kröger, Jack Khouri, Carmelo Gurnari, Joseph McGuirk, Polina Stepensky, Al-Ola Abdallah, Carlos Fernández de Larrea
PURPOSE: Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T. PATIENTS AND METHODS: This is an international retrospective observational study including patients with RRMM infused with currently available commercial or academically produced anti-B-cell maturation antigen (BCMA) CAR-T...
February 15, 2024: Journal of Clinical Oncology